Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12053219rdf:typepubmed:Citationlld:pubmed
pubmed-article:12053219lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C0005423lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C2699153lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C1269955lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:12053219lifeskim:mentionsumls-concept:C0059438lld:lifeskim
pubmed-article:12053219pubmed:issue6lld:pubmed
pubmed-article:12053219pubmed:dateCreated2002-6-7lld:pubmed
pubmed-article:12053219pubmed:abstractTextBased on recent evidence that tea consumption contributes to a decreased incidence of human carcinomas, a number of investigators have focused on the mechanisms of cancer prevention by tea extracts, especially green tea polyphenols. Epigallocatechin-3-gallate (EGCG) is a representative polyphenol that inhibits the activity of the cyclin-dependent kinases of cdk2 and cdk4. This suggests that EGCG may exert its growth-inhibitory effects through modulation of G1 regulatory proteins such as cdk2 and cdk4. The human biliary tract carcinoma cells (TGBC-2, SK-ChA-1, and NOZC-1) were treated with different doses of EGCG (0, 25, 50, 100, and 200 mM) for 48 hours in cell medium. Cell proliferation was analyzed by WST-1 colorimetric assay. For the cell-invasion analysis, the cells were incubated with 100 mM of EGCG for 2 hours. The cells were then added into a Matrigel-coated Cell Insert. After incubation at 37 degrees C for 24 hours, the cells visible through the Matrigel were counted under the microscope. All human biliary tract cancer cells studied showed a significant suppression of cell growth by EGCG treatment in a dose-dependent manner (27.2%, 16.0%, and 10.1%, in TGBC-2, SK-ChA-1, and NOZC-1, respectively, at the dose of 200 mM). Epigallocatechin-3-gallate treatment also produced a significant suppression of invasive ability of the carcinoma cells (12.6%, 11.2%, 7.9%, in TGBC-2, SK-ChA-1, and NOZC-1, respectively, at a dose of 100 mM). These data indicated that EGCG might be a potent biological inhibitor of human biliary tract cancers, reducing their proliferative and invasive activities.lld:pubmed
pubmed-article:12053219pubmed:languageenglld:pubmed
pubmed-article:12053219pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12053219pubmed:citationSubsetIMlld:pubmed
pubmed-article:12053219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12053219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12053219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12053219pubmed:statusMEDLINElld:pubmed
pubmed-article:12053219pubmed:monthJunlld:pubmed
pubmed-article:12053219pubmed:issn0364-2313lld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:KurodaYoshika...lld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:SuzukiYasuyuk...lld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:AjikiTetsuoTlld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:KuYonsonYlld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:TakadaMoriats...lld:pubmed
pubmed-article:12053219pubmed:authorpubmed-author:HabaraKazutoKlld:pubmed
pubmed-article:12053219pubmed:issnTypePrintlld:pubmed
pubmed-article:12053219pubmed:volume26lld:pubmed
pubmed-article:12053219pubmed:ownerNLMlld:pubmed
pubmed-article:12053219pubmed:authorsCompleteYlld:pubmed
pubmed-article:12053219pubmed:pagination683-6lld:pubmed
pubmed-article:12053219pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:meshHeadingpubmed-meshheading:12053219...lld:pubmed
pubmed-article:12053219pubmed:year2002lld:pubmed
pubmed-article:12053219pubmed:articleTitleInhibitory effect of epigallocatechin-3-gallate on growth and invasion in human biliary tract carcinoma cells.lld:pubmed
pubmed-article:12053219pubmed:affiliationFirst Department of Surgery, Kobe University School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.lld:pubmed
pubmed-article:12053219pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12053219lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12053219lld:pubmed